{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T21:10:50Z","timestamp":1771881050708,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,2,18]],"date-time":"2013-02-18T00:00:00Z","timestamp":1361145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,2,18]],"date-time":"2013-02-18T00:00:00Z","timestamp":1361145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1038\/leu.2013.50","type":"journal-article","created":{"date-parts":[[2013,2,18]],"date-time":"2013-02-18T14:34:44Z","timestamp":1361198084000},"page":"1715-1721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy"],"prefix":"10.1038","volume":"27","author":[{"given":"T","family":"Scullen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Santo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Vallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Fulciniti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Cirstea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Nemani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Yee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Mahindra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Raje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,18]]},"reference":[{"key":"BFleu201350_CR1","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-10-1804","volume":"17","author":"N Raje","year":"2011","unstructured":"Raje N, Roodman GD . Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res 2011; 17: 1278\u20131286.","journal-title":"Clin Cancer Res"},{"key":"BFleu201350_CR2","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1200\/JCO.1989.7.12.1909","volume":"7","author":"R Bataille","year":"1989","unstructured":"Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Baldet P et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 1989; 7: 1909\u20131914.","journal-title":"J Clin Oncol"},{"key":"BFleu201350_CR3","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","volume":"108","author":"N Giuliani","year":"2006","unstructured":"Giuliani N, Rizzoli V, Roodman GD . Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006; 108: 3992\u20133996.","journal-title":"Blood"},{"key":"BFleu201350_CR4","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1080\/10428190802005191","volume":"49","author":"S Vallet","year":"2008","unstructured":"Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC . Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma 2008; 49: 1238\u20131245.","journal-title":"Leuk Lymphoma"},{"key":"BFleu201350_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1756-8722-2-36","volume":"2","author":"V Kotla","year":"2009","unstructured":"Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009; 2: 36.","journal-title":"J Hematol Oncol"},{"key":"BFleu201350_CR6","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1038\/leu.2008.174","volume":"22","author":"I Breitkreutz","year":"2008","unstructured":"Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008; 22: 1925\u20131932.","journal-title":"Leukemia"},{"key":"BFleu201350_CR7","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1073\/pnas.0911929107","volume":"107","author":"S Vallet","year":"2010","unstructured":"Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA 2010; 107: 5124\u20135129.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu201350_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1046\/j.1365-2141.2000.01985.x","volume":"109","author":"Y Matsuo","year":"2000","unstructured":"Matsuo Y, Drexler HG, Nishizaki C, Harashima A, Fukuda S, Kozuka T et al. Human bone marrow stroma-dependent cell line MOLP-5 derived from a patient in leukaemic phase of multiple myeloma. Br J Haematol 2000; 109: 54\u201363.","journal-title":"Br J Haematol"},{"key":"BFleu201350_CR9","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1038\/onc.2009.510","volume":"29","author":"L Santo","year":"2010","unstructured":"Santo L, Vallet S, Hideshima T, Cirstea D, Ikeda H, Pozzi S et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene 2010; 29: 2325\u20132336.","journal-title":"Oncogene"},{"key":"BFleu201350_CR10","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1158\/1078-0432.CCR-09-0426","volume":"15","author":"S Pozzi","year":"2009","unstructured":"Pozzi S, Vallet S, Mukherjee S, Cirstea D, Vaghela N, Santo L et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res 2009; 15: 5829\u20135839.","journal-title":"Clin Cancer Res"},{"key":"BFleu201350_CR11","first-page":"491","volume":"118","author":"S Mukherjee","year":"2008","unstructured":"Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN et al. Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008; 118: 491\u2013504.","journal-title":"J Clin Invest"},{"key":"BFleu201350_CR12","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1182\/blood-2007-05-093294","volume":"110","author":"S Vallet","year":"2007","unstructured":"Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S et al. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 2007; 110: 3744\u20133752.","journal-title":"Blood"},{"key":"BFleu201350_CR13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/leu.2008.378","volume":"23","author":"N Raje","year":"2009","unstructured":"Raje N, Hideshima T, Mukherjee S, Raab M, Vallet S, Chhetri S et al. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia 2009; 23: 961\u2013970.","journal-title":"Leukemia"},{"key":"BFleu201350_CR14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2353\/ajpath.2008.080243","volume":"173","author":"N Samee","year":"2008","unstructured":"Samee N, Geoffroy V, Marty C, Schiltz C, Vieux-Rochas M, Levi G et al. Dlx5, a positive regulator of osteoblastogenesis, is essential for osteoblast-osteoclast coupling. Am J Pathol 2008; 173: 773\u2013780.","journal-title":"Am J Pathol"},{"key":"BFleu201350_CR15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jcb.22403","volume":"109","author":"GD Roodman","year":"2010","unstructured":"Roodman GD . Pathogenesis of myeloma bone disease. J Cell Biochem 2010; 109: 283\u2013291.","journal-title":"J Cell Biochem"},{"key":"BFleu201350_CR16","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","volume":"106","author":"N Giuliani","year":"2005","unstructured":"Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S et al. Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005; 106: 2472\u20132483.","journal-title":"Blood"},{"key":"BFleu201350_CR17","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1038\/sj.leu.2402295","volume":"15","author":"D Gupta","year":"2001","unstructured":"Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001; 15: 1950\u20131961.","journal-title":"Leukemia"},{"key":"BFleu201350_CR18","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123\u20132132.","journal-title":"N Engl J Med"},{"key":"BFleu201350_CR19","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133\u20132142.","journal-title":"N Engl J Med"},{"key":"BFleu201350_CR20","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","volume":"99","author":"N Mitsiades","year":"2002","unstructured":"Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525\u20134530.","journal-title":"Blood"},{"key":"BFleu201350_CR21","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1038\/sj.onc.1204623","volume":"20","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC . The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001; 20: 4519\u20134527.","journal-title":"Oncogene"},{"key":"BFleu201350_CR22","first-page":"129","volume":"33","author":"S Munemasa","year":"2008","unstructured":"Munemasa S, Sakai A, Kuroda Y, Okikawa Y, Katayama Y, Asaoku H et al. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int J Oncol 2008; 33: 129\u2013136.","journal-title":"Int J Oncol"},{"key":"BFleu201350_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.leukres.2009.07.017","volume":"34","author":"M De Matteo","year":"2010","unstructured":"De Matteo M, Brunetti AE, Maiorano E, Cafforio P, Dammacco F, Silvestris F . Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide. Leuk Res 2010; 34: 243\u2013249.","journal-title":"Leuk Res"},{"key":"BFleu201350_CR24","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1038\/sj.leu.2404843","volume":"21","author":"E Terpos","year":"2007","unstructured":"Terpos E, Dimopoulos MA, Sezer O . The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007; 21: 1875\u20131884.","journal-title":"Leukemia"},{"key":"BFleu201350_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/(SICI)1097-4644(19991101)75:2<206::AID-JCB3>3.0.CO;2-T","volume":"75","author":"T Ikenoue","year":"1999","unstructured":"Ikenoue T, Jingushi S, Urabe K, Okazaki K, Iwamoto Y . Inhibitory effects of activin-A on osteoblast differentiation during cultures of fetal rat calvarial cells. J Cell Biochem 1999; 75: 206\u2013214.","journal-title":"J Cell Biochem"},{"key":"BFleu201350_CR26","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1096\/fj.07-8080com","volume":"21","author":"M Eijken","year":"2007","unstructured":"Eijken M, Swagemakers S, Koedam M, Steenbergen C, Derkx P, Uitterlinden AG et al. The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J 2007; 21: 2949\u20132960.","journal-title":"FASEB J"},{"key":"BFleu201350_CR27","doi-asserted-by":"publisher","first-page":"32760","DOI":"10.1074\/jbc.271.51.32760","volume":"271","author":"K Tanimoto","year":"1996","unstructured":"Tanimoto K, Yoshida E, Mita S, Nibu Y, Murakami K, Fukamizu A . Human activin betaA gene. Identification of novel 5\u2032 exon, functional promoter, and enhancers. J Biol Chem 1996; 271: 32760\u201332769.","journal-title":"J Biol Chem"},{"key":"BFleu201350_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0012-1606(03)00059-9","volume":"257","author":"N Holleville","year":"2003","unstructured":"Holleville N, Quilhac A, Bontoux M, Monsoro-Burq AH . BMP signals regulate Dlx5 during early avian skull development. Dev Biol 2003; 257: 177\u2013189.","journal-title":"Dev Biol"},{"key":"BFleu201350_CR29","doi-asserted-by":"publisher","first-page":"34387","DOI":"10.1074\/jbc.M211386200","volume":"278","author":"MH Lee","year":"2003","unstructured":"Lee MH, Kim YJ, Kim HJ, Park HD, Kang AR, Kyung HM et al. BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem 2003; 278: 34387\u201334394.","journal-title":"J Biol Chem"},{"key":"BFleu201350_CR30","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.cub.2011.06.048","volume":"21","author":"M Clements","year":"2011","unstructured":"Clements M, Pernaute B, Vella F, Rodriguez TA . Crosstalk between Nodal\/activin and MAPK p38 signaling is essential for anterior-posterior axis specification. Curr Biol 2011; 21: 1289\u20131295.","journal-title":"Curr Biol"},{"key":"BFleu201350_CR31","first-page":"586","volume":"12","author":"N Raje","year":"2010","unstructured":"Raje N, Vallet S . Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther 2010; 12: 586\u2013597.","journal-title":"Curr Opin Mol Ther"},{"issue":"Supplement 2","key":"BFleu201350_CR32","first-page":"S221","volume":"44","author":"AW Mulivor","year":"2008","unstructured":"Mulivor AW, Barbosa D, Kumar R, Pearsall AE, Underwood KW, Ucran JA et al. RAP-011, a soluble activin receptor type IIA IgG-Fc-fusion protein, is a novel bone anabolic agent that prevents bone loss in a mouse model of metastatic breast cancer. Bone 2008; 44 (Supplement 2): S221\u2013S222.","journal-title":"Bone"},{"key":"BFleu201350_CR33","doi-asserted-by":"publisher","first-page":"7082","DOI":"10.1073\/pnas.0711263105","volume":"105","author":"RS Pearsall","year":"2008","unstructured":"Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J et al. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci USA 2008; 105: 7082\u20137087.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu201350_CR34","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood.V79.3.773.bloodjournal793773","volume":"79","author":"L Shao","year":"1992","unstructured":"Shao L, Frigon NL, Young AL, Yu AL, Mathews LS, Vaughan J et al. Effect of activin A on globin gene expression in purified human erythroid progenitors. Blood 1992; 79: 773\u2013781.","journal-title":"Blood"},{"key":"BFleu201350_CR35","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1073\/pnas.89.5.1553","volume":"89","author":"M Shiozaki","year":"1992","unstructured":"Shiozaki M, Sakai R, Tabuchi M, Nakamura T, Sugino K, Sugino H et al. Evidence for the participation of endogenous activin A\/erythroid differentiation factor in the regulation of erythropoiesis. Proc Natl Acad Sci USA 1992; 89: 1553\u20131556.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu201350_CR36","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1359\/jbmr.081208","volume":"24","author":"J Ruckle","year":"2009","unstructured":"Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 2009; 24: 744\u2013752.","journal-title":"J Bone Miner Res"},{"key":"BFleu201350_CR37","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","volume":"108","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458\u20133464.","journal-title":"Blood"},{"key":"BFleu201350_CR38","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/blood-2008-12-196238","volume":"114","author":"P Richardson","year":"2009","unstructured":"Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009; 114: 772\u2013778.","journal-title":"Blood"},{"key":"BFleu201350_CR39","doi-asserted-by":"crossref","unstructured":"Abdulkadyrov KM, Salogub GN, Khuazheva NK, Woolf R, Haltom E, Borgstein NG et al. ACE-011, a soluble activin receptor type Iia IgG-Fc fusion protein, increases hemoglobin (Hb) and improves bone lesions in multiple myeloma patients receiving myelosuppressive chemotherapy: preliminary analysis,. Blood 2009; 114, 749 abstract.","DOI":"10.1182\/blood.V114.22.749.749"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201350.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201350","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201350.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T04:14:56Z","timestamp":1714968896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,18]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["BFleu201350"],"URL":"https:\/\/doi.org\/10.1038\/leu.2013.50","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,18]]},"assertion":[{"value":"21 November 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NR is on the advisory board of Celgene, Novartis, Millenium, Onyx and Amgen. NR has research funding from Acetylon Pharmaceuticals Inc. and Eli Lilly. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}